Alnylam Pharmaceuticals Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Alnylam Pharmaceuticals's estimated annual revenue is currently $74.9M per year.
- Alnylam Pharmaceuticals received $445.6M in venture funding in January 2019.
- Alnylam Pharmaceuticals's estimated revenue per employee is $58,659
- Alnylam Pharmaceuticals's total funding is $417.5M.
- Alnylam Pharmaceuticals has 1277 Employees.
- Alnylam Pharmaceuticals grew their employee count by 31% last year.
- Alnylam Pharmaceuticals currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Alnylam Pharmaceuticals?
To those who say impossible, impractical, unrealistic, we say: CHALLENGE ACCEPTED. We are developing an innovative, entirely new class of medicines called RNAi therapeutics to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology - the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today's medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn't have to wait for hope. Alnylam is turning scientific possibility into reality - in August of 2018, the U.S. FDA approval of our first product ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. Our robust RNAi discovery platform and deep pipeline of investigational medicines includes three programs in late-stage clinical development and multiple programs in early-stage clinical development. We are a global and diverse company of more than 850 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Boston Globe Top Place to Work three years in a row! We are based in Cambridge, U.S., with offices in Zug, Switzerland, and Maidenhead, UK, and operations and employees across the U.S. and throughout Europe and Asia. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam) and YouTube. You can also sign up for email updates here: http://www.alnylam.com/signup-for-updates/keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Noriyuki Kawahata||Associate Director, Program And Alliance Management|
|Lauren Palazola||Case Manager|
|Renae Goodridge||Manager, Case|
|Wendell Davis||Senior Director, Pathology|
|Sara Walsh||Senior Manager, Meeting Planning|
|Donna Beccaria||VP, Enterprise Learning|
|Leah El-Sergani||Senior Manager, Business Planning|
|Ally He||Associate Director, Biostatistics|
|Nicholas Park||Senior Manager, Accounting|
|Akshay Vaishnaw||Evp R&d, Chief Medical Officer|
Alnylam Pharmaceuticals News
BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today provided perspective on ...
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note ...
Alnylam Pharmaceuticals Funding
|2003-07-09||$24.6M||Lead Investor: Multi||Article|
|2006-12-18||$101.0M||Undisclosed||America Securities LLC||Article|
|2013-01-16||$125.0M||Undisclosed||JP Morgan Securities LLC, Morgan Stanley & Co LLC||Article|
|2015-01-22||$517.5M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2017-05-25||$413.2M||Undisclosed||Barclays Capital Inc||Article|
|2017-11-14||$675.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2019-01-16||$445.6M||Undisclosed||Barclays Capital Inc||Article|
Alnylam Pharmaceuticals Executive Hires
|2002-12-05||John M. Maraganore||CEO/President||Article|
|2003-04-17||Victor E Kotelianski||VP Research/Opers||Article|
|2003-07-01||Thomas R. Ulich||SVP R/D||Article|
|2003-07-29||Vincent Miles||SVP Business Development||Article|
|2004-06-25||Patricia Allen||VP Finance||Article|
|2006-02-09||Akshay Vaishnaw||Vice President Clinical Research||Article|
|2006-06-15||Sara Nochur||VP Regulatory Affairs||Article|
|2008-10-02||John A. Schmidt||Chief Scientific Officer||Article|
|2010-06-03||Laurence Reid||SVP/Chief Business Officer||Article|
|2011-03-04||Patricia Allen||VP Finance/Treasurer||Article|
|2011-06-14||Akshay K Vaishnaw||Chief Medical Officer||Article|
|2012-06-28||Akshay Vaishnaw||EVP/Chief Medical Officer||Article|
|2014-09-16||Karen Anderson||SVP/Chief Human Resources Officer||Article|
|2014-10-30||Pushkal Garg||SVP Clinical Development||Article|
|2015-06-09||David-Alexandre||SVP/Chief Business Officer||Article|
|2016-09-20||Yvonne Greenstreet||EVP/Chief Operating Officer||Article|
|2017-01-04||Pushkal Garg||Chief Medical Officer||Article|
|2017-05-10||Manmeet Soni||chief financial officer||Article|
|2018-06-21||Masako Nakamura||SVP Head of Asia||Article|
Alnylam Pharmaceuticals New Location/Offices
Alnylam Pharmaceuticals Staff Cuts
|Date||Number of Employees||Location||Reference|
|2010-09-24||20-30 % Jobs||Article|